BioSig Technologies (NASDAQ:BSGM – Get Rating) had its price target dropped by research analysts at Noble Financial to $2.00 in a research note issued on Thursday, Stock Target Advisor reports. Noble Financial’s price objective indicates a potential upside of 392.25% from the stock’s previous close.
Separately, Taglich Brothers reaffirmed a “speculative buy” rating on shares of BioSig Technologies in a research note on Thursday, September 15th.
BioSig Technologies Price Performance
Shares of BioSig Technologies stock opened at $0.41 on Thursday. BioSig Technologies has a 12-month low of $0.25 and a 12-month high of $3.51. The company’s fifty day simple moving average is $0.60 and its two-hundred day simple moving average is $0.76.
Insider Buying and Selling
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Cambridge Investment Research Advisors Inc. raised its holdings in BioSig Technologies by 6.7% in the second quarter. Cambridge Investment Research Advisors Inc. now owns 345,807 shares of the company’s stock worth $228,000 after buying an additional 21,618 shares during the last quarter. Commonwealth Equity Services LLC raised its holdings in BioSig Technologies by 24.2% in the first quarter. Commonwealth Equity Services LLC now owns 125,705 shares of the company’s stock worth $144,000 after buying an additional 24,500 shares during the last quarter. Warberg Asset Management LLC purchased a new position in BioSig Technologies in the second quarter worth about $43,000. Advisor Group Holdings Inc. raised its holdings in BioSig Technologies by 394.9% in the first quarter. Advisor Group Holdings Inc. now owns 85,859 shares of the company’s stock worth $99,000 after buying an additional 68,509 shares during the last quarter. Finally, Truist Financial Corp purchased a new position in BioSig Technologies in the third quarter worth about $114,000. 9.46% of the stock is owned by hedge funds and other institutional investors.
BioSig Technologies Company Profile
BioSig Technologies, Inc, together with its subsidiaries, operates as medical device company. The company's proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time.
- Get a free copy of the StockNews.com research report on BioSig Technologies (BSGM)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Does ASML’s November Rally Have Staying Power?
- Verra Mobility Stock Has Returned Back to the Station
Receive News & Ratings for BioSig Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSig Technologies and related companies with MarketBeat.com's FREE daily email newsletter.